Tags Archive Navigation
icon
-
Media ReleaseNovartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
-
StoryDemystifying the science of myelodysplastic syndromes
-
Media ReleaseNovartis and Hewlett Packard Enterprise join forces to advance Novartis global health efforts
-
Media ReleaseNovartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity
-
StoryExpanding a new digital healthcare solution across chronic heart disease management
-
Media ReleaseNovartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond
-
Media ReleaseNew Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender
-
Media ReleaseNovartis set to achieve 100% renewable electricity in its European operations
-
Media ReleaseNovartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
-
Media ReleaseNovartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year**
-
Media ReleaseEn 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments
-
Media ReleaseNovartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben